We are live on ! Find out more

AMRN

Amarin Corp

AMRN

Market cap $292M

13.84 USD

-0.09

0.65%

At close Updated Sep 16, 4:00 PM EDT

1 day

-0.65%

5 days

-3.01%

1 month

-1.21%

3 months

-8.77%

6 months

-10.25%

Year to date

0.87%

1 year

-7.3%

5 years

-86.62%

10 years

-74.08%

About: Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.

Employees: 80

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 63.6%

Negative 9.1%

Zacks Investment Research

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28t h - 31st, in Munich, Germany.

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript

Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript

Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short

AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.

Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short

Amarin Q2 Earnings Call Highlights

Amarin NASDAQ: AMRN said its second-quarter results reflected progress in its dual commercial strategy, which combines a company-managed U.S. business with partnered commercialization internationally. Management highlighted growing demand for VASCEPA in Europe, cost reductions from a completed restructuring program and a third consecutive quarter of positive operating cash flow.

Amarin Q2 Earnings Call Highlights

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's U.S. Market Share, an Improved OPEX Profile, and Positive Cash Flow Generation DUBLIN, Ireland and BRIDGEWATER, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the second quarter ended June 30, 2026 (Q2 2026) and highlighted positive outlooks associated with the one-year anniversary of its fully partnered international commercial strategy.

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report second quarter 2026 financial results and conduct a conference call on Wednesday, July 29, 2026.

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Zacks Investment Research

Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now

Amarin (AMRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now

See News Rankings

Price charts implemented using Lightweight Charts™